2505
141
81
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9238 |
KI-7
|
Adenosine Receptor | GPCR/G Protein; Neuroscience |
KI-7 是一种A2B 腺苷受体阳性变构调节剂。它增强选择性 A2B 腺苷受体激动剂 BAY 60-6583 和腺苷诱导的 cAMP 积累,EC50分别为 2390 nM 和 2550 nM。它也增强非选择性 A2B 腺苷受体激动剂 NECA 诱导的 cAMP 积累,EC50为 445.8 nM。 | |||
T11758L |
KI696
|
Nrf2 | Immunology/Inflammation |
KI696 是一种高亲和力探针,可有效抑制 Keap1 和 NRF2 的相互作用。 | |||
T2446 |
KI8751
|
EGFR; VEGFR; FGFR; PDGFR; c-Kit | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Ki8751 是一种有效的 VEGFR2 抑制剂,其 IC50=0.9 nM。 | |||
T11758 |
KI696 isomer
|
Nrf2 | Immunology/Inflammation |
KI696 isomer 是 KI696 的异构体,是一种亲和力较低的探针,可用于研究免疫和代谢疾病。 | |||
T6108 |
Ki16425
Debio 0719 |
LPA Receptor; LPL Receptor | GPCR/G Protein |
Ki16425 (Debio 0719) 是一种竞争性、有效和可逆的 LPA1、LPA2 和 LPA3 拮抗剂,Ki 分别为 0.34、6.5 和 0.93 μM。它可抑制LPA 诱导的 HEK293A 细胞中 YAP/TAZ 的去磷酸化,降低LPA 诱导的 p42/p44 MAPK 激活。 | |||
T6347 |
Ki16198
|
LPA Receptor; LPL Receptor | GPCR/G Protein |
Ki16198 是一种可口服的 LPA 受体拮抗剂,是 Ki16425 的甲酯衍生物。它抑制 LPA1 和 LPA3 诱导的肌醇磷酸的Ki 值分别为 0.34 和 0.93 μM,可用于胰腺癌发生和转移的研究。 | |||
T4315 |
Ki20227
N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 |
c-Fms; VEGFR; CSF-1R; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Ki20227 是一种高效的、口服具有活性的、选择性的CSF1R(c-Fms 酪氨酸激酶)抑制剂,对 CSF1R,VEGFR2,c-Kit 和PDGFRβ的IC50分别为 2 nM,12 nM,451 nM 和 217 nM。它可以阻止破骨细胞分化和溶骨性破坏。 | |||
T68313 |
KI-328
|
||
KI-328 is a novel KIT inhibitor. KI-328 shows selective potency against KIT kinase for the in vitro kinase assay, and inhibits the growth of wild-type (Wt)- and mutant-KIT-expressing cells, while it has little potency against D816V-KIT. | |||
T69162 |
Ki23057
|
||
Ki23057 is a a FGFR2 inhibitor, which enhances the chemosensitivity of drug-resistant gastric cancer cell lines when used in combination with chemotherapeutic drugs. Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16. The apoptosis process might be the main mechanism underlying the synergistic effect of these combinations. The ERCC1 and p53 genes may play an integral role in the synergism betwee... | |||
T74402 |
FAP-PI3KI1
|
||
FAP-PI3KI1 是一种成纤维细胞活化蛋白 (FAP) 靶向 PI3K 抑制剂,可选择性靶向表达 FAP 的人特发性肺纤维化 (IPF)细胞并有效抑制胶原蛋白合成,减少胶原蛋白沉积。 | |||
T4607 |
CAY 10465
CAY10465,CAY10465 Exclusive |
AhR; Aryl Hydrocarbon Receptor | Immunology/Inflammation; Metabolism |
CAY 10465 是一种选择性和高亲和力的芳香烃受体(AhR)激动剂,Ki 值为 0.2 nM。 | |||
T10261 |
AGN 196996
|
Others; Retinoid Receptor; Autophagy | Autophagy; Metabolism; Others |
AGN 196996是一种高效且具有选择性的RARα抑制剂(Ki:2 nM)。AGN 196996对RARβ和RARγ的亲和性极低,Ki 分别为1087 nM 和8523 nM。 | |||
T27800 |
LAS38096
LAS 38096,LAS-38096 |
Adenosine Receptor | GPCR/G Protein; Neuroscience |
LAS38096 是一种A2B 腺苷受体拮抗剂(Ki :17 nM),具有强效性、选择性和高效性 。 | |||
T5587 |
CGP71683 hydrochloride
CGP71683A,盐酸CGP71683 |
Neuropeptide Y Receptor | GPCR/G Protein; Neuroscience |
CGP71683 hydrochloride (CGP71683A) 是竞争性的神经肽受体拮抗剂,Ki 值为 1.3 nM。 | |||
TQ0084 |
lumateperone Tosylate
ITI-007,Lumateperone甲苯磺酸盐 |
Dopamine Receptor; 5-HT Receptor | GPCR/G Protein; Neuroscience |
lumateperone Tosylate (ITI-007) 是5-HT 2A 受体拮抗剂,Ki 为 0.54 nM,突触前 D2受体的部分激动剂和突触后 D2受体的拮抗剂,Ki 为 32 nM。 | |||
T15712 |
Laropiprant
MK-0524 |
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
Laropiprant (MK-0524) 是 DP receptor 的选择性拮抗剂,Ki 为 0.57 nM,对 TP 受体的 Ki 为 2.95 nM。 | |||
T2373 |
Vipadenant
CEB-4520,BIIB-014 |
Adenosine Receptor | GPCR/G Protein; Neuroscience |
Vipadenant (CEB-4520) 是一种腺苷受体拮抗剂,抑制 A2A 和 A1 活性的 Ki 值分别为 1.3 和 68 nM。 | |||
T23782 |
Benzolamide
CL-11366,W 1803,CL 11366,CL11366,苯唑拉胺,W-1803 |
Carbonic Anhydrase | Metabolism |
Benzolamide (CL 11366) 是碳酸酐酶 (CA) 抑制剂,抑制hCA I(Ki:15 nM)、hCA II(Ki:9 nM)、EcoCAγ(Ki:94 nM)、VchCAγ(Ki:78 nM)、CAS3(Ki:54 nM)。它可用于研究青光眼和癫痫。 | |||
T15682 |
L-371,257
|
Oxytocin Receptor; Vasopressin Receptor | Endocrinology/Hormones; GPCR/G Protein |
L-371,257 是催产素受体的竞争性拮抗剂,pA2 为 8.4,Ki 为 19 nM。 L-371,257 对加压素受体 1a 的 Ki 值为 3.7 nM。 | |||
T41247 |
Thioperamide maleate
MR-12842 maleate,硫丙咪胺马来酸 |
Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
Thioperamide maleate (MR-12842 maleate) 是一种有效且选择性的 H3 受体拮抗剂 (Ki = 4.3 nM),可抑制 [3H]histamine 的合成 (Ki = 31 nM)。 | |||
T15595L |
IRL-1620 acetate
IRL-1620 acetate(142569-99-1 free base) |
Endothelin Receptor | GPCR/G Protein |
IRL-1620 acetate 是一种有效的特异性内啡肽 B 受体 (ETB) 激动剂,Ki 为 16 pM,相比于ETA,其Ki 为 19 μM。 | |||
T37696 |
NOS1-IN-1
nNOS Inhibitor I |
NOS | Immunology/Inflammation |
NOS1-IN-1(nNOS Inhibitor I) 是一种强效、选择性和细胞渗透性 nNOS 抑制剂(Ki:120 nM)。NOS1-IN-1 对 eNOS 的 Ki 值为 39 μM,对 iNOS 的 Ki 值为 325 μM。 | |||
T39284 |
EST73502 HCl
|
Opioid Receptor | Endocrinology/Hormones; GPCR/G Protein; Neuroscience |
EST73502 是 μ-阿片受体激动剂 (Ki = 64 nM) 激动剂和 σ1 受体拮抗剂 (Ki = 118 nM)。 EST73502 显示出镇痛活性。 | |||
T15270 |
Fananserin
RP 62203,法南色林 |
Dopamine Receptor; 5-HT Receptor | GPCR/G Protein; Neuroscience |
Fananserin 是一种有效的、特异性的、口服活性的 5-HT2 拮抗剂(大鼠 5-HT2A 的 Ki = 0.37 nM)。 Fananserin 是人 D4 受体的拮抗剂 (Ki = 2.93 nM)。 | |||
T1749 |
AL 082D06
D-06,AL082D06 |
Glucocorticoid Receptor | Endocrinology/Hormones |
AL 082D06 (D-06) 是非甾体类糖皮质激素受体 (GR) 选择性拮抗剂(Ki:210 nM)。 | |||
T14069 |
A-3 hydrochloride
|
CaMK; Casein Kinase; PKA; PKC | Chromatin/Epigenetic; Cytoskeletal Signaling; Metabolism; Neuroscience; Stem Cells; Tyrosine Kinase/Adaptors |
A-3 hydrochloride 是一种细胞可渗透的、可逆的、ATP 竞争性非选择性拮抗剂。它抑制 PKA 、酪蛋白激酶 II 和肌球蛋白轻链激酶,Ki 值分别为4.3 µM、5.1 µM 和7.4 µM。它还抑制 PKC 和酪蛋白激酶 I 的活性,Ki 分别为 47 µM 和 80 µM。 | |||
T7343 |
PF-04979064
|
PI3K; mTOR | PI3K/Akt/mTOR signaling |
PF-04979064 是一种选择性 PI3K/mTOR 双重激酶抑制剂,能够抑制 PI3Kα (Ki=0.13 nM) 和 mTOR (Ki=1.42 nM)。 | |||
T1865 |
S1RA
E-52862,4-(2-((5-甲基-1-(2-萘基)-1H-吡唑-3-基)氧基)乙基)吗啉 |
Sigma receptor | GPCR/G Protein |
S1RA (E-52862) 是一种有效且特异性的 sigma-1受体拮抗剂,Ki 为17nM,对 σ2R 具有良好的选择性,Ki 值大于 1000 nM。 | |||
T0713 |
Drofenine hydrochloride
盐酸六氢芬宁,Hexahydroadiphenine hydrochloride |
AChE | Neuroscience |
Drofenine hydrochloride (Hexahydroadiphenine hydrochloride) 是竞争性胆碱酯酶抑制剂,ki=3 uM。 | |||
T28531 |
Facinicline hydrochloride
RG3487 |
5-HT Receptor; AChR | GPCR/G Protein; Neuroscience |
Facinicline hydrochloride (RG3487) 是一种口服有效的烟碱α7 receptor 部分激动剂,对人 nAChR 的 Ki 值为 6 nM。它可改善啮齿类动物的认知和感觉运动门控。它与5-HT3受体结合的 Ki 为 1.2 nM。 | |||
T2420 |
PHT-427
PHT 427,CS-0223 |
Apoptosis; Akt; PDK | Apoptosis; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
PHT-427 (CS-0223) 是一种 Akt 和 PDPK1双重抑制剂,与 Akt 和 PDPK1 中的 PH 结构域有亲和性,Ki 分别为 2.7 μM 和 5.2 μM。 | |||
T8419 |
XP-59
|
SARS-CoV | Microbiology/Virology |
XP-59 是一种 SARS-CoV Mpro 抑制剂,其 Ki 值为 0.1 nM。 | |||
T14151 |
AKR1C1-IN-1
|
NADPH | Metabolism |
AKR1C1-IN-1 是高选择性 AKR1C1抑制剂(Ki:4 nM)。 | |||
T2009 |
SB-3CT
|
MMP | Proteases/Proteasome |
SB-3CT 是一种可透过血脑屏障的、竞争性的金属蛋白酶MMP-2和MMP-9抑制剂,Ki 分别为 13.9 nM、600 nM。他对明胶酶具有高选择性。它具有神经保护和抗癌作用。 | |||
T15811 |
LY2955303
|
Others; Retinoid Receptor | Metabolism; Others |
LY2955303 是一种有效的特异性视黄酸受体 γ 拮抗剂(RARγ,Ki = 1.09 nM)。 | |||
T10691 |
CAY10595
|
GPR | Endocrinology/Hormones; GPCR/G Protein |
CAY10595 是 CRTh2 (DP2) 受体的拮抗剂,Ki 为 10 nM。 | |||
T35347 |
Et-29
NRD167 |
Sirtuin | Chromatin/Epigenetic; DNA Damage/DNA Repair |
Et-29 是一种特异性的 SIRT5 抑制剂,Ki 为 40 nM。 | |||
T2688 |
LY310762
LY310762 HCl |
5-HT Receptor | GPCR/G Protein; Neuroscience |
LY310762 是 5-HT1D 受体拮抗剂,Ki 为 249 nM。 | |||
T2017 |
U-104
NSC-213841,MST-104 |
Carbonic Anhydrase | Metabolism |
U-104 (NSC-213841) 是 CA IX 和 CA XII 碳酸酐酶 (CA) 抑制剂,其 Ki 分别为 45.1 nM 和 4.5 nM。小鼠模型中,它能够表现出明显的抑制肿瘤生长的作用。 | |||
T12306 |
OMDM-5
|
Cannabinoid Receptor; Endogenous Metabolite; TRP/TRPV Channel | GPCR/G Protein; Membrane transporter/Ion channel; Metabolism |
OMDM-5 是有效的、选择性的anandamide 细胞摄取抑制剂,Ki 为 4.8 μM。它是VR1 (TRPV1)激动剂,EC50为 75 nM,显示出对大麻素 1 型受体 (CB1) 的弱配体活性 (Ki=4.9 μM)。 | |||
T11799 |
L-745870 hydrochloride
|
Dopamine Receptor | GPCR/G Protein; Neuroscience |
L-745870 hydrochloride 是可透过血脑屏障的、选择性的、具有口服活性的多巴胺 D4受体拮抗剂,Ki=0.43 nM。它对 D2(Ki 为 960 nM) 和 D3(Ki 为 2300 nM) 受体的亲和力相对较弱,对 5-HT2受体,sigma 位点和 α-肾上腺素受体表现出中等亲和力。 | |||
T1913 |
MK-3697
|
OX Receptor | GPCR/G Protein; Neuroscience |
MK3697是OX2受体的一种高效选择性拮抗剂,Ki 值为0.95nM。 | |||
T22128 |
OU749
|
Transferase | Metabolism |
OU749 是一种 γ-谷氨酰转移酶 (GGT) 抑制剂,固有 Ki 值为 17.6 μM。 | |||
T7292 |
FITM
4-氟-N-[4-[6-(异丙基氨基)嘧啶-4-基]-1,3-噻唑-2-基]-N-甲基苯甲酰胺 |
GluR | Neuroscience |
FITM 是mGlu1受体的一种负变构调节剂,Ki 值为2.5 nM。 | |||
T6022 |
LY404039
pomaglumetad |
Glucocorticoid Receptor; GluR | Endocrinology/Hormones; Neuroscience |
LY404039 (pomaglumetad) 是可口服的mGluR2和mGluR3选择性激动剂,有抗精神病和抗焦虑的作用。它对重组人mGluR2和mGluR3的Ki 分别为 149 和 92 nM,比对其他受体/转运蛋白的抑制性高 100 倍以上。 | |||
T22959 |
m-Chlorophenylbiguanide hydrochloride
1-(3-Chlorophenyl)biguanidehydrochloride,1-(3-氯苯基)双胍 |
5-HT Receptor | GPCR/G Protein; Neuroscience |
m-Chlorophenylbiguanide hydrochloride 是一种 5-HT3 受体激动剂。它选择性结合 5-HT3(Ki: 0.002 µM) 超过 5-HT1A(Ki: 10 µM) 和 5-HT2(Ki: 10 µM) 受体,但也结合多巴胺转运蛋白上的高亲和力和低亲和力位点( DAT;IC50:在大鼠尾状壳核突触体膜中分别为 0.4 和 34.8 µM)。 | |||
T5943 |
4,4'-DIMETHOXYBENZIL
p-Anisil,4,4'-二甲氧基苯酚酯 |
Others | Others |
4,4'-Dimethoxybenzil (trans-4-Sphingenine) 是人肠胃羧基酯酶抑制剂(Ki:70 nM)。 | |||
T7412 |
Tandospirone citrate
SM-3997 citrate,坦度螺酮柠檬酸盐,枸橼酸坦度螺酮 |
5-HT Receptor | GPCR/G Protein; Neuroscience |
Tandospirone citrate (SM-3997 citrate) 是一种选择性5-HT1A 受体激动剂,Ki 为27 nM。 | |||
T5047 |
PD-168077 maleate
|
Dopamine Receptor | GPCR/G Protein; Neuroscience |
PD-168077 maleate 是多巴胺 D4受体选择性激动剂,其 Ki=9 nM。 | |||
T26690 |
AVN-101
|
5-HT Receptor; Adrenergic Receptor; Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
AVN-101 是一种非常有效的 5-HT7 受体拮抗剂 (Ki = 153 pM)。 AVN-101 还对组胺 H1 (Ki = 0.58 nM) 和肾上腺素能 α2A、α2B 和 α2C (Ki = 0.41-3.6 nM) 受体表现出相当高的亲和力。 AVN-101在中枢神经系统疾病动物模型中显示出良好的口服生物利用度和促进脑血屏障通透性、低毒性和合理的疗效。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2922 |
Phlorizin
Floridzin,根皮甙,根皮苷,NSC 2833,Phloridzin |
ATPase; SGLT | GPCR/G Protein; Membrane transporter/Ion channel |
Phlorizin (Phloridzin) 是非选择性的SGLT 抑制剂,也是Na+/K+-ATPase 抑制剂,对于hSGLT1和hSGLT2的Ki 值分别为 300 和 39 nM。 | |||
T4S2354 |
Dimethylfraxetin
二甲基白蜡树亭,Fraxetin dimethyl ether,6,7,8-Trimethoxycoumarin |
Carbonic Anhydrase | Metabolism |
Dimethylfraxetin (6,7,8-Trimethoxycoumarin) 是Carbonic anhydrase 抑制剂(Ki:0.0097 μM)。 | |||
T8182 |
Guanfu base A
Guan-fu base A,关附甲素 |
P450; Potassium Channel; HER | Angiogenesis; JAK/STAT signaling; Membrane transporter/Ion channel; Metabolism; Tyrosine Kinase/Adaptors |
Guanfu base A 是一种生物碱,分离自 Aconitum coreanum,是非竞争性 CYP2D6抑制剂,对人肝微粒体 (HLM) 的 Ki 为 1.20 μM,对人重组体 (rCYP2D6) 的 Ki 为 0.37 μM。它也是 CYP2D 的有效竞争抑制剂。它还能抑制 HERG 通道电流。Guan-fu base A 具有抗心律失常的作用。 | |||
T9605 |
Sangivamycin
BA-90912,桑霉素,NSC 65346 |
Nucleoside Antimetabolite/Analog; PKC | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair |
Sangivamycin (NSC-65346) 是蛋白激酶 C (PKC) 的有效抑制剂 (Ki = 10 μM)。 Sangivamycin 对多种人类癌症细胞具有抗增殖活性。 | |||
T8260 |
4',5-Dihydroxyflavone
|
Lipoxygenase; Glucosidase | Metabolism |
4',5-Dihydroxyflavone 是大豆 LOX-1,Ki=102.6 μM。它也是一种酵母 α-葡萄糖苷酶抑制剂,IC50=66 μM。 | |||
TN5752 |
Isorhapontin
|
Antifungal | Microbiology/Virology |
Isorhapontin 抑制木霉属纤维二糖水解酶 I (Ki = 57.2 μM) 和木霉属内切葡聚糖酶 I 的活性。Isorhapontin 具有抗真菌活性。 | |||
T2209 |
Serotonin hydrochloride
5-HT hydrochloride,5-羟基色胺盐酸盐,5-HT HCl,Serotonin HCl,5-Hydroxytryptamine hydrochloride |
5-HT Receptor; Endogenous Metabolite; Transferase | GPCR/G Protein; Metabolism; Neuroscience |
Serotonin hydrochloride (Serotonin HCl) 是一种内源性 5-HT 受体激动剂、CNS 中的单胺神经递质和儿茶酚 O-甲基转移酶 (COMT) 抑制剂,Ki 值为 44 μM。 | |||
T15686 |
L-741626
3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole |
Dopamine Receptor | GPCR/G Protein; Neuroscience |
L-741626 (3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole) 是D2多巴胺受体选择性拮抗剂,对人 D2、D3 和 D4 受体的Ki 分别为 2.4、100 和 220 nM。 | |||
T4429 |
Rauwolscine hydrochloride
Corynanthidine hydrochloride,盐酸育亨宾碱,萝芙素盐酸盐,α-Yohimbine hydrochloride,Isoyohimbine hydrochloride |
Adrenergic Receptor | GPCR/G Protein; Neuroscience |
Rauwolscine hydrochloride (Isoyohimbine hydrochloride) 是一种高选择性的 α2 adrenergic 受体拮抗剂,Ki=12 nM。 | |||
T8373 |
6-Diazo-5-oxo-L-nor-Leucine
DON,L-6-Diazo-5-oxonorleucine,6-重氮-5-氧代-L-正亮氨酸,Diazooxonorleucine |
Influenza Virus; Glutaminase; Antibacterial; Antibiotic | Microbiology/Virology; Proteases/Proteasome |
6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine) 是一种谷氨酰胺拮抗剂,具有抗菌、抗病毒和抗癌作用,其Ki 值为 6 μM。它能降低肿瘤细胞的自我更新能力和转移能力 ,在体外表现出遗传毒性。 | |||
TN1160 |
1,2,3,6-Tetragalloylglucose
1,2,3,6-Tetra-O-galloyl-β-D-glucose,1,2,3,6-四-O-没食子酰-Β-D-葡萄糖,TeGG |
LDL; UGT | Metabolism |
1,2,3,6-Tetragalloylglucose (TeGG) 是 UDP-葡萄糖醛酸转移酶 1 家族成员,是多肽A1 的抑制剂(Ki:1.68 μM)。 | |||
TN1472 |
Cassiaside
|
Beta-Secretase; BACE | Neuroscience |
Cassiaside 是一种萘甲酮糖苷,抑制 BACE1 (IC50= 4.45 μM; Ki=9.85 μM)。Cassiaside 对半乳糖胺损伤具有明显的肝脏保护作用, 具有潜在的抗阿尔茨海默病 (AD) 活性。 | |||
T5648 |
Purpurin
吡啉,1,2,4-Trihydroxyanthraquinone,Hydroxylizaric acid,Verantin |
MAO; Antibacterial; Antibiotic; Antifungal | Metabolism; Microbiology/Virology; Neuroscience |
Purpurin (Verantin) 是来自Rubia tinctorumL. 的天然蒽醌,具有抗抑郁样作用。 | |||
T0687 |
Simvastatin
辛伐他汀,MK-0733,MK 733 |
Apoptosis; Mitophagy; Ferroptosis; HMG-CoA Reductase; Autophagy | Apoptosis; Autophagy; Metabolism |
Simvastatin (MK 733) 是一种 HMG-CoA 还原酶抑制剂 (Ki=0.2 nM),具有口服活性。Simvastatin 具有降血脂活性,可以抑制肝脏产生胆固醇,还可以用于预防心血管疾病。 | |||
T6856 |
Halofuginone
卤夫酮,常山酮,Tempostatin,empostatin,RU-19110 |
Calcium Channel; DNA/RNA Synthesis; Sodium Channel; Parasite; TGF-beta/Smad | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Membrane transporter/Ion channel; Metabolism; Microbiology/Virology; Stem Cells |
Halofuginone (RU-19110) 是Febrifugine 的衍生物,是一种竞争性脯氨酰-tRNA 合成酶抑制剂。它也是肺血管扩张剂,可激活Kv 通道并阻断电压门控、受体操作和存储操作的钙离子通道。它具有抗炎、抗癌、抗疟疾和抗纤维化作用。 | |||
TN1016 |
Kukoamine A
|
NF-κB; Lipoxygenase; DNA/RNA Synthesis; Parasite | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism; Microbiology/Virology; NF-κB |
Kukoamine A 是一种天然的精胺衍生物,具有抗癌、抗高血压、细胞保护、抗氧化和抗炎活性。它是锥虫硫磷还原酶抑制剂,Ki 值为 1.8 μM。 | |||
TN3013 |
4,5-Dimethoxycanthin-6-one
Methylnigakinone |
P450; Antibacterial; PDE | Metabolism; Microbiology/Virology |
4,5-Dimethoxycanthin-6-one 从 Picrasma quassioides BENNET (Simaroubaceae)是一种从 Picrasma quassioides BENNET (Simaroubaceae) 中分离得到生物碱。4,5-Dimethoxycanthin-6-one 是一种有效的、非竞争性的 CYP1A2 介导的 phenacetin O-deethylation 抑制剂(IC50 : 1.7 μM, Ki : 2.6 μM),对环磷酸腺苷(cAMP)磷酸二酯酶有很强的抑制作用。4,5-Dimethoxycanthin-6-one 具有抗菌活性,对金黄色葡萄球菌及其耐药菌株有抑制作用。4,5-Dimethoxycanthin-6-one 对肿瘤细胞株 U937 和 HepG2 具有细胞毒性。 | |||
TN1120 |
Osthenol
|
MAO; Monoamine Oxidase | Metabolism; Neuroscience |
Osthenol 是一种前酰化香豆素,从独活干根中分离得到。它对重组 hMAO-A 具有潜在的选择性抑制作用,IC50=0.74 µM,对 hMAO-A 和 hMAO-B 表现出较高的选择性指数。它是一种可逆的,选择性的竞争性人单胺氧化酶-A(hMAO-A)抑制剂 (Ki=0.26 µM)。 | |||
T10941 |
D-Ribonolactone
D-(+)-核糖酸-1,4-内酯,D-核糖内酯 |
Endogenous Metabolite; Antibacterial | Metabolism; Microbiology/Virology |
D-Ribonolactone 是一种大肠杆菌 β-半乳糖苷酶的抑制剂,Ki 为 26 mM。它也一种糖内酯。 | |||
T4000 |
(±)-Equol
Equol,(±)-雌马酚,(R,S)-Equol |
Estrogen Receptor/ERR; Estrogen/progestogen Receptor; Drug Metabolite | Endocrinology/Hormones; Metabolism |
(±)-Equol ((R,S)-Equol) 是 equol 的外消旋体。它对 ERα 和 ERβ 的 EC50s of 分别为 200 和 74 nM。Equol 是大豆异黄酮黄豆苷和大豆黄素的代谢产物。 | |||
T2144 |
Tacrolimus
他克莫司,Fujimycin,FK506,FR900506 |
Phosphatase; Others; Antibacterial; Antibiotic; mTOR; Autophagy | Autophagy; Metabolism; Microbiology/Virology; Others; PI3K/Akt/mTOR signaling |
Tacrolimus (Fujimycin) 可与 FKBP12 结合形成高亲和力复合物 (Ki: 0.2 nM),抑制钙/钙调蛋白依赖性蛋白磷酸酶的活性。 | |||
TN1736 |
Hibifolin
棉皮素-8-O-Β-D-葡萄糖醛酸苷,棉花皮素-8-O-葡萄糖醛酸苷 |
Adenosine deaminase | Metabolism |
Hibifolin 是一种黄酮醇糖苷,是潜在的腺苷脱氨酶抑制剂。它可以保护神经元免受 beta-淀粉样蛋白诱导的毒性。 | |||
TN1849 |
Kuwanon H
|
GPR; Bombesin Receptor | Endocrinology/Hormones; GPCR/G Protein |
Kuwanon H 是分离自桑白皮的黄酮类化合物,具有拮抗非肽类蛙皮素受体的活性。Kuwanon H 特异性抑制细胞内胃泌激素释放肽 CRP 与GRP-preferring 受体的结合,Ki 为 290 nM。 | |||
T6430 |
Calcifediol
25-羟基维生素 D3,U 32070E,25-hydroxy Vitamin D3,RO 8-8892,骨化二醇 |
Endogenous Metabolite | Metabolism |
Calcifediol (U 32070E) 是由维生素 D3 在肝中经羟基化后得到的前激素,是 VDR 的有效抑制剂。 | |||
T5081 |
Adenine monohydrochloride hemihydrate
腺嘌呤盐酸盐,Adenine hydrochloride hydrate,6-Aminopurine hydrochloride hydrate |
Endogenous Metabolite; Adenosine Receptor | GPCR/G Protein; Metabolism; Neuroscience |
Adenine monohydrochloride hemihydrate 是内源性代谢产物的一种。 | |||
TQ0296L |
N-Nornuciferine hydrochloride(4846-19-9 free base)
N-Nornuciferine hydrochloride |
P450 | Metabolism |
N-Nornuciferine hydrochloride(4846-19-9 free base) (N-Nornuciferine hydrochloride) 是荷叶中的一种 aporphine 生物碱,显着抑制 CYP2D6(IC50:3.76 μM,Ki:2.34 μM)。 | |||
TN3748 |
D-Asparagine
D-天冬酰胺,H-D-Asn-OH |
Others; Endogenous Metabolite | Metabolism; Others |
D-Asparagine (H-D-Asn-OH) 是酵母菌株的氮源。 D-Asparagine 是 L-Asparagine 水解的竞争性抑制剂 (Ki = 0.24 mM)。 | |||
T10191L |
7-Chlorokynurenic acid
7-chloro-4-hydroxy-2-carboxyquinoline,7-氯犬尿酸,7-CKA |
GluR; NMDAR | Neuroscience |
7-Chlorokynurenic acid (7-chloro-4-hydroxy-2-carboxyquinoline) 是一种有效的选择性 NMDA 受体拮抗剂,对甘氨酸 B 激动剂位点的 IC50 为 0.56 μM。 7-Chlorokynurenic acid 抑制谷氨酸再摄取到突触小泡中,Ki 为 0.59 μM,并在神经轴输送后显示出镇痛作用。 | |||
T2926 |
Schizandrin A
|
P450; Virus Protease; Autophagy | Autophagy; Metabolism; Microbiology/Virology |
Schisandrin A 是一种从东方药物五味子中提取的主要有效成分,抑制 CYP3A 活性,IC50 分别为 6.60 μM 和 Ki 为 5.83 μM。 | |||
T2770 |
Gentiopicroside
Gentiopicrin,龙胆苦甙,龙胆苦苷 |
P450; HCV Protease | Metabolism; Microbiology/Virology; Proteases/Proteasome |
Gentiopicroside (Gentiopicrin) 是天然环烯醚萜苷,具有抗炎和抗氧化活性。它抑制P450的活性,对 CYP2A6 的 IC50和 Ki 值分别为 61 µM 和 22.8 µM, | |||
TN1650 |
Friedelin
软木三萜酮,无羁萜 |
P450; NOS; Caspase; Prostaglandin Receptor | Apoptosis; GPCR/G Protein; Immunology/Inflammation; Metabolism; Proteases/Proteasome |
Friedelin 是分离自 Maytenus ilicifolia(Mart) 的叶子。它是 CYP3A4的非竞争性抑制剂,其 IC50和 Ki 分别为10.79 μM 和 6.16 μM,也是 CYP2E1的竞争性抑制剂,其 IC50和 Ki 分别为 22.54 μM 和 18.02 μM。 | |||
T13539 |
Allopurinol riboside
|
Others; Endogenous Metabolite; Parasite; Drug Metabolite | Metabolism; Microbiology/Virology; Others |
Allopurinol riboside 是别嘌醇的代谢产物,具有抗寄生虫作用。 Allopurinol riboside 竞争性抑制嘌呤核苷磷酸化酶对肌苷的作用,Ki 为 277 μM。 | |||
T5564 |
Tricarballylic acid
β-Carboxyglutaric acid,1,2,3-Propanetricarboxylic acid,三碳烯丙酸,Carballylic acid,Propane-1,2,3-tricarboxylic acid,丙三酸 |
aconitase; Mitochondrial Metabolism | Metabolism |
Tricarballylic acid (Carballylic acid) 是三碳烯丙酸酯的共轭酸,是一种乌头酸水合酶的竞争性抑制剂,其 Ki= 0.52 mM。 | |||
T5568 |
H-Tyr(3-I)-OH
3-碘-L-酪氨酸,3-Iodo-L-tyrosine |
Endogenous Metabolite | Metabolism |
H-Tyr(3-I)-OH (3-Iodo-L-tyrosine) 是酪氨酸羟化酶抑制剂和甲状腺激素 的中间体。 | |||
T14853 |
Cabergoline
FCE-21336,卡麦角林 |
Dopamine Receptor; 5-HT Receptor; Autophagy | Autophagy; GPCR/G Protein; Neuroscience |
Cabergoline (FCE-21336) 是一种麦角衍生的多巴胺 D2亚类受体激动剂,高亲和力作用于D2、D3和5-HT2B 受体,Ki 分别为 0.7、1.5 和 1.2。 | |||
T7671 |
Myosmine
麦司明,麦斯明 |
Others; AChR | Neuroscience; Others |
Myosmine 是存在于木贼中的一种烟草生物碱,对 a4b2 烟碱乙酰胆碱受体具有低亲和力,Ki 值为 3300 nM。 | |||
T5S0669 |
Bergamottin
5-Geranoxypsoralen,Bergamotine,Bergaptin,佛手柑素 |
P450 | Metabolism |
Bergamottin (5-Geranoxypsoralen) 是竞争性CYP1A1抑制剂(Ki:10.703 nM)。 | |||
T2O2744 |
alpha-Naphthoflavone
苯并黄素;α-萘黄酮;7,8-苯并黄酮,7,8-benzoflavone,α-萘黄酮 |
Aromatase | Endocrinology/Hormones |
alpha-Naphthoflavone (7,8-benzoflavone) 是合成的黄酮类化合物,是一种竞争性芳香酶抑制剂,其IC50=0.5 μM,Ki=0.2 μM。 | |||
T5S0994 |
N-Methylcytisine
N-甲基野靛碱,Caulophylline |
Others; AChR | Neuroscience; Others |
N-Methylcytisine (Caulophylline) 是苦参中的一种三环喹啉类生物碱,具有降血糖、缓解疼痛和抗炎活性。它是中枢神经系统中乙酰胆碱烟碱受体的选择性配体,对鱿鱼视神经节中的烟碱乙酰胆碱受体具有很高的亲和力,Kd 为 50 nM。 | |||
T3149 |
Salvianolic Acid C
丹酚酸C,丹酚酸 C |
Others; P450 | Metabolism; Others |
Salvianolic acid C 是一种细胞色素 P4502C8(CYP2C8)的非竞争性抑制剂及细胞色素 P4502J2(CYP2J2)中等强度的混合抑制剂,对 CYP2C8 和 CYP2J2 的 Ki 分别为 4.82 μM 和 5.75 μM。 | |||
TN2268 |
Tetrahydromagnolol
|
Cannabinoid Receptor; GPR; GABA Receptor | Endocrinology/Hormones; GPCR/G Protein; Membrane transporter/Ion channel; Neuroscience |
Tetrahydromagnolol 是 Magnolol 的主要代谢产物,是一种弱的GPR55受体拮抗剂。它是选择性大麻素CB2受体激动剂,EC50为 170 nM,Ki 为 416 nM,对CB2受体的选择性比 CB1 受体高 20 倍。 | |||
T1310 |
2-Thiouracil
Thiouracil,硫代由雪,Deracil,2-硫脲嘧啶 |
Thyroid hormone receptor(THR); NO Synthase | Endocrinology/Hormones; Immunology/Inflammation |
2-Thiouracil (Deracil) 是神经型一氧化氮合酶 (nNOS) 的选择性抑制剂(Ki:20 μM),是一种抗甲状腺化合物,可用作高度特异性的黑色素瘤探测物。 | |||
T4S0051 |
Coptisine sulfate
|
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
Coptisine Sulfate 是一种从黄连中分离到的生物碱,是非竞争性的IDO 抑制剂,Ki=为 5.8 μM,IC50=6.3 μM。 | |||
T1717 |
alpha-Mangostin
α-倒捻子素,α-Mangostin,Mangostin |
Apoptosis; Virus Protease; Dehydrogenase; Reactive Oxygen Species; Antibacterial; Antifungal | Apoptosis; Immunology/Inflammation; Metabolism; Microbiology/Virology; NF-κB |
alpha-Mangostin (Mangostin) 是有多种生物活性的膳食呫吨酮。它是一种IDH1突变体的抑制剂,Ki 值为 2.85 μM。 | |||
T7472 |
7-Hydroxyflavone
7-羟基黄酮,7羟基黄酮 |
P450 | Metabolism |
7-Hydroxyflavone 是一种黄酮类化合物,从M. indica 中分离得到,具有抗炎活性。它利用 ERK/Nrf2/HO-1 通路保护肾细胞,使其免受尼古丁诱导的细胞毒性。 | |||
T1711 |
Harmine
Telepathine,去氢骆驼蓬碱 |
MAO; 5-HT Receptor; DYRK | Cell Cycle/Checkpoint; GPCR/G Protein; Metabolism; Neuroscience; Tyrosine Kinase/Adaptors |
Harmine (Telepathine) 是一种从山茱萸种子中分离出来的生物碱,具有抗癌和抗炎活性。它是双特异性酪氨酸磷酸化调节激酶抑制剂,对5-HT2A 血清素受体具有高亲和力,Ki 值为 397 nM。 | |||
T20712 |
Conessine
Conessinum,Wrightine,地麻素,Roquessine,Neriine,Konessin |
Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
Conessine (Conessinum) 是一种具有抗疟活性的甾体生物碱,是高效选择性H3 受体拮抗剂,对于人、狗、豚鼠和大鼠 H3受体的Ki 分别为 5.4、6.0、5.7 和 25 nM。 | |||
T4S0145 |
Corylifol A
Corylinin,补骨脂异黄酮A |
hCE; STAT; UGT | JAK/STAT signaling; Metabolism; Stem Cells |
Corylifol A (Corylinin) 是补骨脂中的一种天然产物,可抑制IL-6 诱导的STAT3激活和磷酸化,IC50值为0.81 μM。 | |||
T11218 |
ε-Viniferin
epsilon-Viniferin,Epsilon-白藜芦醇脱氢二聚体 |
P450 | Metabolism |
ε-Viniferin (epsilon-Viniferin) 提取自 Vitis vinifera,是 Resveratrol 的二聚体,能够抑制 CYP 家族,其 Ki=0.5~20 μM,具有抗氧化作用。 | |||
T1270 |
Vincristine sulfate
Leurocristine,22-Oxovincaleukoblastine sulfate,Leurocristine sulfate,硫酸长春新碱 |
Apoptosis; Microtubule Associated | Apoptosis; Cytoskeletal Signaling |
Vincristine sulfate (Leurocristine sulfate) 是一种抗肿瘤长春花生物碱。在细胞周期的 S 期不可逆地与微管(Ki: 85 nM) 和纺锤体蛋白结合,并干扰有丝分裂纺锤体的形成。 | |||
------------------------ 更多 ------------------------ |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01827 |
CD30/TNFRSF8 Protein, Human, Recombinant (His)
D1S166E,tumor necrosis factor receptor superfamily, member 8... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 40 kDa and the accession number is P28908-1. | |||
TMPY-03105 |
Ki67/MKI67 Protein, Human, Recombinant (GST)
MIB-1,PPP1R105,marker of proliferation Ki-67,MIB-,<... |
Human | E. coli |
MKI67 contains 1 FHA domain and plays a key role in cell proliferation. During interphase, the MKI67 antigen can be exclusively detected within the cell nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes. MKI67 protein is present during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from resting cells. MKI67 is an excellent marker to determine the growth fraction of a given cell population. The fraction of MKI67-positive tu... | |||
TMPY-05443 |
CD30/TNFRSF8 Protein, Mouse, Recombinant (His)
Ki-1,Ki,D1S166E,Cd30,tumor necrosis factor... |
Mouse | HEK293 Cells |
CD30/TNFRSF8 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.6 kDa and the accession number is Q60846. | |||
TMPY-05737 |
CD30/TNFRSF8 Protein, Mouse, Recombinant (hFc)
Cd30,Ki,tumor necrosis factor receptor superfamily,... |
Mouse | HEK293 Cells |
CD30/TNFRSF8 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 51.92 kDa and the accession number is Q60846. | |||
TMPY-01888 |
KRAS Protein,Human, Recombinant (Q61H, His)
KRAS2,C-K-RAS,Kirsten rat sarcoma viral oncogene ho... |
Human | E. coli |
KRAS Protein,Human, Recombinant (Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22.5 kDa and the accession number is P01116-2. | |||
TMPY-04116 |
KRAS Protein,Human,Recombinant(G12C & Q61H, His)
NS,CFC2,K-RAS4B,C-K-RAS,KRAS2,K-RAS2B,K-RAS,Kirsten... |
Human | E. coli |
KRAS Protein,Human,Recombinant(G12C & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2. | |||
TMPY-06056 |
KRAS Protein, Human, Recombinant (G12D, His)
KRAS1,K-RAS4B,Kirsten rat sarcoma viral oncogene ho... |
Human | E. coli |
KRAS Protein, Human, Recombinant (G12D, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22 kDa and the accession number is P01116-2. | |||
TMPY-04113 |
KRAS Protein,Human,Recombinant(G12D & Q61H, His)
Kirsten rat sarcoma viral oncogene homolog,KRAS2, |
Human | E. coli |
KRAS Protein,Human,Recombinant(G12D & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2. | |||
TMPJ-01436 |
MKI67 Protein, Human, Recombinant (GST)
Ki-67,Antigen Ki67,MKI67,KI |
Human | E. coli |
MKI67 also also known as Ki67, is a 350-400 kDa nuclear protein that belongs to a molecular group comprised of mitotic chromosome-associated proteins. MKI67 contains 1 FHA domain and plays a key role in cell proliferation. MKI67 is contextually expressed, being potentially found in all cells that are not in the Go phase of the cell cycle. Thus, MKI67 qualifies as a cell proliferation marker. It is also associated with ribosomal RNA transcription. Inactivation of antigen MKI67 leads to inhibition... | |||
TMPY-05471 |
CD30/TNFRSF8 Protein, Human, Recombinant (hFc)
Ki-1,tumor necrosis factor receptor superfamily, me... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 65.2 kDa and the accession number is P28908-1. | |||
TMPY-06282 |
CD30/TNFRSF8 Protein, Human, Recombinant (hFc & Avi), Biotinylated
tumor necrosis factor receptor superfamily, member 8,Ki<... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 67.02 kDa and the accession number is P28908-1. | |||
TMPY-03614 |
PSME3 Protein, Human, Recombinant (His)
PA28G,PA28-gamma,HEL-S-283,REG-GAMMA,proteasome (prosome, ma... |
Human | E. coli |
PSME3, also known as PA28-gamma, is a subunit of proteasome. The 26S proteasome multicatalytic proteinase complex has a highly ordered structure composed of 2 complexes, a 2S core and a 19S regulator. The 2S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 1 non-ATPase su... | |||
TMPY-05118 |
CD30/TNFRSF8 Protein, Human, Recombinant (His), Biotinylated
D1S166E,Ki-1,tumor necrosis factor receptor superfa... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 39.9 kDa and the accession number is P28908-1. | |||
TMPY-06430 |
CD30/TNFRSF8 Protein, Human, Recombinant (His & Avi), Biotinylated
Ki-1,CD30,D1S166E,tumor necrosis factor receptor su... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 41.74 kDa and the accession number is P28908-1. | |||
TMPJ-00510 |
KRAS Protein, Human, Recombinant (G12C, His)
RASK2,c-K-ras,CFC2,KRAS2,Ki-Ras |
Human | E. coli |
KRAS Protein, Human, Recombinant (G12C, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 26 KDa and the accession number is AAH13572.1. | |||
TMPJ-00511 |
KRAS Protein, Human, Recombinant (G12V, His)
KRAS2,RASK2,c-K-ras,Ki-Ras,CFC2 |
Human | E. coli |
KRAS Protein, Human, Recombinant (G12V, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 25-30 KDa and the accession number is AAH13572.1. | |||
TMPK-00078 |
CD27 Ligand/CD70 Trimer Protein, Human, Recombinant (His), FITC-Labeled
TNFSF7, Ki-24 antigen,CD70,TNFSF7G,CD70 molecule,CD... |
Human | HEK293 Cells |
CD70, also named CD27 ligand (CD27L), is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7. CD70 is a cytokine that binds to CD27. Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. CD27 Ligand/CD70 Trimer Protein, Human, Recombinant (His), FITC-Labeled is expressed in HEK293 mammalian cells with N-His tag. The predicted molecular weight is 51.8 kDa and ... | |||
TMPK-00080 |
CD27 Ligand/CD70 Trimer Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated
CD27-L,CD70 molecule,TNFSF7G,CD70,CD27LG,CD27 Ligand,TNFSF7,... |
Human | HEK293 Cells |
CD70, also named CD27 ligand (CD27L), is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7. CD70 is a cytokine that binds to CD27. Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. CD27 Ligand/CD70 Trimer Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with N-His tag. The predicted molecula... | |||
TMPK-00666 |
CD27 Ligand/CD70 Protein, Cynomolgus, Recombinant (His)
CD70 molecule,TNFSF7,CD70,TNFSF7G,CD27-L,CD27LG,CD27 Ligand,... |
Cynomolgus | HEK293 Cells |
CD70, also named CD27 ligand (CD27L), is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7. CD70 is a cytokine that binds to CD27. Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. CD27 Ligand/CD70 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with N-His tag. The predicted molecular weight is 18.4 kDa and the accession nu... | |||
TMPK-00079 |
CD27 Ligand/CD70 Trimer Protein, Human, Recombinant (His)
TNFSF7,CD27 Ligand, Ki-24 antigen,CD70 molecule,CD2... |
Human | HEK293 Cells |
CD70, also named CD27 ligand (CD27L), is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7. CD70 is a cytokine that binds to CD27. Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. CD27 Ligand/CD70 Trimer Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with N-His tag. The predicted molecular weight is 51.8 kDa and the accession ... | |||
TMPJ-00342 |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, His)
Lymphocyte activation antigen CD30,TNFRSF8,Tumor necrosis fa... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 60-95 KDa and the accession number is P28908. | |||
TMPJ-00341 |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, hFc)
TNFRSF8,Ki-1 antigen,CD30,CD30L receptor,Tumor necr... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, hFc) is expressed in HEK293 mammalian cells with C-Fc tag. The predicted molecular weight is 90-120 KDa and the accession number is P28908. | |||
TMPJ-00340 |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, His & Avi), Biotinylated
Lymphocyte activation antigen CD30,TNFRSF8,CD30,Ki-... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-6xHis-Avi tag. The predicted molecular weight is 60-90 KDa and the accession number is P28908. | |||
TMPJ-00343 |
CD30/TNFRSF8 Protein, Human, Recombinant (mFc)
TNFRSF8,Tumor necrosis factor receptor superfamily member 8,... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with C-mFc tag. The predicted molecular weight is 90-120 KDa and the accession number is P28908. | |||
TMPJ-00240 |
CAMK1 Protein, Human, Recombinant (His)
CaM Kinase I Alpha,CaMKI-α,CaM Ki... |
Human | HEK293 Cells |
Calcium/Calmodulin-Dependent Protein Kinase Type 1 (CAMK1) belongs to the protein kinase superfamily, CAMK Ser/Thr protein kinase family, and CaMK subfamily. CAMK1 contains one protein kinase domain and widely expressed. CAMK1 is phosphorylated by CaMKK1 and CaMKK2 on Thr-177. CAMK1 regulates transcription activators activity, cell cycle, hormone production, cell differentiation, actin filament organization, and neurite outgrowth. CAMK1 plays a role in K+ and ANG2-mediated regulation of the aldo... | |||
TMPK-01428 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
CFC2,K-RAS4B,K-Ras 2,C-K-RAS,RASK2,NS3,RALD,KI-RAS,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01405 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
KI-RAS,RASK2,K-Ras 2,MHC,KRAS,KRAS1,NS3,K-RAS2A,K-R... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01443 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled
KRAS1,C-K-RAS,K-RAS4B,RALD,K-Ras 2,K-RAS2A,K-RAS2B,KRAS2,NS3... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS2B,K-Ras 2,C-K-RAS,RASK2,K-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01462 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS4A,K-RAS2A,CFC2,KRAS1,K-RAS4B,C-K-RAS,KRAS,K-RAS2B,K-Ra... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01511 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
GTPase Kras,K-RAS4A,KI-RAS,K-RAS4B,C-K-RAS,K-Ras 2,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01460 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,K-RAS2A,KI-RAS,K-RAS4B,RALD,NS3,GTPase Kras,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01402 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
KRAS1,NS,CFC2,K-RAS4B,RASK2,K-Ras 2,KI-RAS,GTPase K... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01430 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-RAS2A,RALD,NS3,K-Ras 2,KI-RAS,NS,MHC,K-RAS2B,K-RA... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01432 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC2,MHC,KRAS,KI-RAS,K-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01440 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
RASK2,KI-RAS,C-K-RAS,KRAS,MHC,NS,K-RAS4A,K-RAS2B,CF... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01528 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPase Kras,K-Ras 2,KI... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B,KI-RAS,K... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01512 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,NS,NS3,K-RAS2B,CFC2,MHC,KRAS1,GTPase Kras,K-RAS4A,KR... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01465 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS2A,CFC2,KRAS,GTPase Kras,K-RAS2B,K-Ras 2,KI |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01435 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
KRAS2,NS3,RASK2,KI-RAS,RALD,K-RAS2B,K-RAS4B,GTPase ... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01438 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
RASK2,KRAS2,KRAS1,MHC,C-K-RAS,KI-RAS,K-RAS4B,RALD,K... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01507 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)
K-RAS2A,K-RAS4B,KI-RAS,RALD,C-K-RAS,RASK2,NS,MHC,NS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01427 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2A,KRAS2,CFC2,RASK2... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01403 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase Kras,KRAS,K-RAS4B,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01399 |
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS2A,NS3,KRAS2,CFC2,K-RAS4B,GTPase Kras,RALD,MHC,KRAS,RAS... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01404 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,RALD,K-RAS4A,K-RAS2A,K-RAS4B,K-RAS2B... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01479 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,KRAS1,K-Ras 2,K-RAS2A,K-RAS2B,C-K-RAS,K-RAS4A,CFC2,KRAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01525 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase Kras,KRAS2,K-RAS4B,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01461 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS2A,MHC,CFC2,K-RAS4B,K-RAS2B,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
------------------------ 更多 ------------------------ |